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Eligibility for home treatment of deep vein thrombosis: prospective study Thomas Schwarz, Benjamin Schmidt, Ulrike Höhlein, Jan Beyer, Hans-Egbert Schröder, Sebastian M Schellong Low molecular weight heparin is safe and effective for the treatment of deep vein thrombosis. 1 We have recently shown in a randomised study that immobilisation is not necessary. 2 The results challenge the traditional notion that these patients must be treated in hospital. For selected patients, outpatient treatment has been shown to be safe and effective.
3 4 We determined the proportion of patients who still require admission to hospital and why.
Methods and results
Between 1 November 1998 and 15 August 1999 all patients presenting to the vascular diagnostics unit of the University Hospital Dresden, Germany, as outpatients with acute deep vein thrombosis in the leg were prospectively evaluated regarding eligibilty for home treatment. We defined acute deep vein thrombosis as non-compressible deep veins on ultrasonography (UM9 HDI, linear array 4-7 MHz, ATL, Bothell, Washington, DC) and symptoms that had been present for less than two weeks. Written informed consent was obtained from all patients.
On the day of diagnosis patients were started on oral anticoagulation with phenprocoumon (adjusted to a target international normalised ratio of 2-3) and the low molecular weight heparin nadroparin (90 IU/kg body weight twice daily) until a therapeutic ratio was achieved. All patients received class II compression stockings. At presentation, the decision regarding hospital admission was based on medical reasons, home care situation, patients' and general practitioners' rejection of outpatient treatment, and hospital service logistics. The 95% confidence intervals were calculated according to the Wilson procedure.
We assessed recurrent venous thromboembolism (verified by sonography, ventilation-perfusion scan, or pulmonary angiography), major bleeding, and death at clinical follow up of patients treated at home. Assessments were at three and six days and two, four, and 12 weeks after initiation of treatment. The study was approved by the local ethics committee.
A total of 117 consecutive outpatients (48 men, 69 women) were diagnosed as having acute deep vein thrombosis. Of these, 92 received home treatmentthat is, they were not admitted at all. The median (range) age was 62.0 (19-95) years. Three patients were admitted to hospital for medical reasons; 11 because of the home care situation; and 11 for reasons of hospital service logistics (table). At the 12 week follow up of the 92 patients, eight had died (six from cancer and two from chronic heart failure; three had recurrent thrombosis; and four had developed minor bleeding. No clinical pulmonary embolism or major bleeding occurred. Safety and efficacy figures are similar to those previously published.
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Comment
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Competing interests: None declared. Clozapine (Clozaril, Novartis), a tricyclic dibenzodiazepine derivative, has an established role in the treatment of refractory schizophrenia. In the United Kingdom the drug may only be prescribed by consultant psychiatrists registered with the Clozaril Patient Monitoring Service; this reflects the serious adverse effect profile of the drug, which includes agranulocytosis. Paradoxical hypertension with increased concentrations of urinary catecholamines has also been reported, albeit rarely and in association with other antipsychotic treatment.
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We describe four patients with a pseudophaeochromocytoma syndrome associated with clozapine. All had serious refractory psychiatric disturbances. Case 2 presented to a cardiology clinic with hypertension for which she was receiving bendrofluazide 2.5 mg daily, and case 3 was referred to a diabetes clinic with type 2 diabetes (treated with metformin 500 mg twice daily) and dyslipidaemia. Case 4 was initially referred to a renal clinic with hypertension. Profuse sweating, hypertension, and obesity were common to all the patients; intermittent tachycardia was noted in cases 1 to 3 (table) . Renal and hepatic function were normal in all the patients, and there was no evidence of alternative causes of secondary hypertension. The interval between the start of clozapine treatment and the development of the clinical features varied (table), being evident within one week in case 1. Urinary catecholamine concentrations, measured in 24 hour collections during clozapine treatment, were increased in all four patients (table). To exclude the possibility of phaeochromocytoma, case 1 underwent computed tomography and cases 3 and 4 underwent isotopic imaging.
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In cases 1 and 2, urinary catecholamine concentrations normalised, and clinical features improved or resolved after withdrawal of the drug; these patients also lost several kilograms in body weight. Clozapine was continued at a lower dose in case 3 as the supervising psychiatrist advised against its withdrawal. Treatment was also continued in case 4 because his blood pressure settled spontaneously.
The neuropharmacological actions of clozapine are complex and include affinity for 5-HT 2 receptors and for adrenergic receptors in vitro.
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Clozapine has been reported to cause increases in plasma noradrenaline concentrations, a postulated mechanism being the inhibition of resynaptic reuptake mediated by 2 adrenergic receptors.
4 Sulpiride, which blocks presynaptic 2 adrenoreceptors, may have contributed to the clinical features in cases 2 and 4. 
